Literature DB >> 7354151

Skin manifestations of pentazocine abuse.

R F Palestine, J L Millns, G T Spigel, A L Schroeter.   

Abstract

Seventeen patients who had cutaneous complications following pentazocine injections are presented. The mean age was 50 years; total daily pentazocine dose ranged from 60 to 2,400 mg; evidence of psychiatric illness was present in 94%, and previous drug or alcohol abuse was noted in 65%. Fifty-three percent of our series of patients had a medical or paramedical background. Eighteen percent had diabetes mellitus, and 65% had a personal or family history (or both) of diabetes. A hypothesis is presented for this association. Characteristic histologic findings included fibrosis of the dermis and panniculus, with vascular alterations, fat necrosis with granulomatous inflammation, and vascular thrombosis with occasional endarteritis. We emphasize that medical and paramedical personnel and patients with a personal or family history of diabetes should be added to the group of patients considered to be at special risk for cutaneous complications of pentazocine injections.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7354151     DOI: 10.1016/s0190-9622(80)80292-1

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  Epidemiology of scleroderma.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

2.  Case Report: Injectable pentazocine abuse leading to necrotizing soft tissue infection and florid osteomyelitis.

Authors:  Colin Mudrick; Jonathan Isaacs; Jessica Frankenhoff
Journal:  Hand (N Y)       Date:  2011-09-09

3.  New-onset systemic sclerosis and scleroderma renal crisis under docetaxel.

Authors:  Véronique Debien; Arthur Petitdemange; Dorothée Bazin; Carole Ederle; Benoit Nespola; Hamid Merdji; Jérome Olagne; Thierry Martin; Aurélien Guffroy; Carole Pflumio
Journal:  J Scleroderma Relat Disord       Date:  2021-04-13

Review 4.  Drug-induced arthritis and arthralgia.

Authors:  F D Hart
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

5.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).

Authors:  J D Reveille; E Durban; M J MacLeod-St Clair; R Goldstein; R Moreda; R D Altman; F C Arnett
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Multiple Skin Abscesses and Myofibrosis of Bilateral Lower Limbs Following Repeated Intramuscular Injection of Pentazocine with Concomitant Tuberculous Infection.

Authors:  Vikas M Agashe; Hitendra Patil; Manit K Gundavda
Journal:  J Orthop Case Rep       Date:  2015 Jan-Mar

7.  Encounter of plastic surgeons with pentazocine abuse: Lack of awareness or information overloaded.

Authors:  Neeti Neha; Veena Singh; Nandesh Kumar
Journal:  Indian J Plast Surg       Date:  2018 May-Aug

Review 8.  Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective.

Authors:  Marta Cossu; Lorenzo Beretta; Petra Mosterman; Maria J H de Hair; Timothy R D J Radstake
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

9.  Clinical and socio-demographic determinants of pentazocine misuse among patients with sickle cell disease, Benin City, Nigeria: a case-control study.

Authors:  Ademola Adewoyin; Oluwafemi Adeyemi; Nosimot Davies; Matilda Ojo
Journal:  Pan Afr Med J       Date:  2019-10-14

10.  Pentazocine-induced contractures: Dilemma in management.

Authors:  Dileep Kumar; Anil Gupta; V P Sharma; Ganesh Yadav; Arpita Singh; Ajay Kumar Verma
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.